Scan how Ionis Pharmaceuticals compares to other late stage healthcare stories by reviewing our curated 36 healthcare AI stocks that could see sentiment shift quickly as new clinical data lands.
To own Ionis Pharmaceuticals, you need to be comfortable with a commercialising biotech that still reports losses while leaning heavily on a growing rare disease and cardiometabolic portfolio. The analyst consensus Narrative on Simply Wall St frames the thesis around execution in APOC3, neurology and partnered programs that can shift the business toward self funded growth over time.
The recent DAWNZERA data helps strengthen the hereditary angioedema story but does not change that the most important near term catalyst is commercial uptake of TRYNGOLZA, ZANVASTRO and other launched drugs. The biggest risk remains clinical and legal overhangs from eplontersen and pelacarsen, which could limit confidence in future royalty streams.
The reaffirmed 2026 revenue guidance of US$875 million to US$900 million ties directly into this. It keeps attention on whether Ionis Pharmaceuticals can sustain current collaboration and product momentum while managing a net loss that was US$109.97 million in Q3 and US$317.15 million across the first nine months of 2026.
For a catalyst stack built around new launches and royalties, that guidance becomes a reference point when you line it up against DAWNZERA data and broader pipeline execution. If the business tracks near the top of that range without outsized cash burn, it may help offset concerns that prior trial setbacks and any related shareholder actions distract management at a critical scaling phase.
Ionis Pharmaceuticals' narrative projects US$2.1b revenue and US$204.3 million earnings by 2029. This assumes 29.5% yearly revenue growth and an earnings increase of about US$750.8 million from current earnings of a US$546.5 million loss.
Uncover why Ionis Pharmaceuticals' fair value indicates a 138% potential upside to its current price that may not be available for long.
One alternate angle on Ionis Pharmaceuticals focuses on pricing risk rather than DAWNZERA’s efficacy. Under that more cautious script, analysts worried that rare disease reimbursement pressure might cap future earnings, even while some of the lowest forecasts still pencilled in around US$1.9b revenue and about US$353.1 million earnings by 2029 before this new data. That gap in expectations shows how wide opinions can run. It is worth comparing several viewpoints and then deciding how this fresh DAWNZERA readout might shift your own.
Explore 3 other Ionis Pharmaceuticals fair value estimates, including one that suggests it could be worth just $60.32!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Ionis Pharmaceuticals may sit at the center of your watchlist right now, but your best edge often comes from lining it up against a broader bench of potential opportunities. The Simply Wall St Screener can help you quickly surface other stocks that match the kind of risk, income, or balance sheet profile you want to pair with a biotech like this.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com